SCHEMBL4875280

SCHEMBL4875280

Nc1nc(Cl)c2c(n1)-c1ccccc1SCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADORA2A P29274 3/20 0.38
ADORA1 P30542 3/20 0.38
NPY5R Q15761 5/20 0.38
MAPK14 Q16539 1/20 0.37
ADRB2 P07550 1/20 0.35
CYP3A4 P08684 1/20 0.35
HTR1A P08908 1/20 0.35
HTR1D P28221 1/20 0.35
DRD3 P35462 1/20 0.35
HTR2B P41595 1/20 0.35
HTR5A P47898 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
BCHE P06276 2/20 0.35
HRH4 Q9H3N8 2/20 0.35
HRH2 P25021 1/20 0.35
HRH1 P35367 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875687 0.83 HPGD (0.42) HPGDNPSR1ADORA2AADORA1NPY5R
SCHEMBL4877494 0.76 MAPK14 (0.39) ADORA2AADORA1MAPK14BCHEHRH4
SCHEMBL4877642 0.76 BCHE (0.57) HPGDNPSR1ADORA2AADORA1BCHE
SCHEMBL607367 0.75 HRH4 (0.67) HTR2BHRH4HRH2HRH1HRH3
SCHEMBL4874208 0.74 NPY5R (0.43) HPGDADORA2AADORA1NPY5RMAPK14
SCHEMBL3341967 0.74 BCHE (0.59) NPSR1ADORA2AADORA1BCHEHRH4
SCHEMBL605000 0.72 HRH4 (0.67) HRH4HRH2HRH1HRH3
SCHEMBL606066 0.72 HRH4 (0.67) HRH4HRH2HRH1HRH3
SCHEMBL4878260 0.71 KDM4E (0.47) HPGDADORA2AADORA1BCHEHRH4
SCHEMBL4876988 0.69 ADORA2A (0.37) ADORA2AADORA1MAPK14BCHEHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735411-B2 Macrocyclic benzofused pyrimidine derivatives ABBVIE INC. (US) 2014-05-27 US disclosed
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives ABBVIE INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188452-A1 Macrocyclic Benzofused Pyrimidine Derivatives DPYD, TYMS, UMPS HPGD 175/4885NPSR1 4769/4885ADORA2A 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.